Effects of T. Brucei infection on the pharmacokinetics of DB868 and DB829

Effects of T. Brucei infection on the pharmacokinetics of DB868 and DB829

Claudia is currently working with the compound DB868, a prodrug that is a lead candidate for the treatment of the CNS stage of Human African Sleeping Sickness.  Her research includes elucidating the pathway of biotransformation of DB868 into its active compound (DB829) and the enzymes that are involved in this pathway.  Additionally, she will assess the changes in activity and expression of these enzymes during infection with the parasite Trypanosoma brucei and will ultimately look at the overall changes in disposition of DB829 in an in vivo rat model of the infection.